Author of

• 12592

  +

  P3.10 - Poster Session 3 - Chemotherapy (ID 210)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 12628

    +

    P3.10-036 - Afatinib in Platinum- and Gefitinib or Erlotinib-pretreated Patients with NSCLC. A single Institution experience in a compassionate-use-program (ID 2124)

    09:30 - 09:30  |  Author(s): N. Reinmuth
    • Abstract

    Background
    Backround and Rationale: The inhibition of the Epidermal Growth Factor Receptor (EGFR) is a treatment option in patients with non-small cell lung cancer (NSCLC). Afatinib is an inhibitor of EGFR as well as the other members of the ErbB family. This compassionate use program was initiated to offer a treatment option for patients after failure of platinum-based chemotherapy and reversible TKI.

    Methods
    Material and Methods: Patients with NSCLC who had had platinum-based chemotherapy and therapy with gefitinib or erlotinib for at least 6 months or who had an activating mutation in the EGFR-gene were eligible to enter this compassionate use program. Patients were given 50 mg (or 40 mg at the investigators´ decision) of afatinib daily until progression or intolerable adverse events. Here we report on our clinical experience at our institution.

    Results
    Results: 18 Patients were enrolled at our center. 6 had an activating mutation, 1 had proven wild type and 11 had an unknown EGFR-status. The median duration of therapy was 2.4 months (range 0.5 to > 19 months). Interestingly, one of the remissions was observed in a patient with proven EGFR wild-type. Most adverse events were EGFR-TKI class-specific and manageable by dose-adaption.

    Conclusion
    Conclusions: Afatinib is an appropriate treatment option for patients who benefitted from treatment with gefitinib or erlotinib.